Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Finished Goods (2016 - 2025)

Historic Finished Goods for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $20.2 million.

  • Collegium Pharmaceutical's Finished Goods rose 2312.65% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 2312.65%. This contributed to the annual value of $17.8 million for FY2024, which is 1712.26% up from last year.
  • Collegium Pharmaceutical's Finished Goods amounted to $20.2 million in Q3 2025, which was up 2312.65% from $20.2 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Finished Goods ranged from a high of $36.9 million in Q1 2022 and a low of $9.5 million during Q2 2021
  • For the 5-year period, Collegium Pharmaceutical's Finished Goods averaged around $16.5 million, with its median value being $15.2 million (2023).
  • In the last 5 years, Collegium Pharmaceutical's Finished Goods soared by 28078.47% in 2022 and then crashed by 6280.54% in 2023.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Finished Goods stood at $12.7 million in 2021, then grew by 27.77% to $16.2 million in 2022, then dropped by 6.29% to $15.2 million in 2023, then grew by 17.12% to $17.8 million in 2024, then rose by 13.64% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q3 2025, $20.2 million for Q2 2025, and $18.5 million during Q1 2025.